Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript

Dr. Mark Goldsmith: Oh, I see. I’m sorry. So, you’re asking about for the RMC-9805 trial for our G12D selective inhibitor. Do we expect the demographics of the patient population to match the demographics of the real world patient population? Is that what you’re asking?

Ben Burnett: Exactly.

Dr. Mark Goldsmith: Yes. I think to a large degree, that’s true. I don’t think it’s specifically designed that way. It’s an old tumors eligibility, but that basically ends up meaning that you’ll get something that represents, the real world, and G12D mutations are predominantly found in gastrointestinal tumors. G12D is the, I think, the third most common lung cancer mutation, but it’s the first most common mutation across all solid tumors and across all gastrointestinal tumors. So, yes, I think gastrointestinal tumors will be most common.

Operator: This concludes the question-and-answer session. I’d now like to turn it back to Mark for closing remarks.

Dr. Mark Goldsmith: Thank you, operator, and thanks to everyone for participating today and for your continued support of Revolution Medicines.

Operator: Thank you for your participation in today’s conference. This concludes the program. You may now disconnect.